Media stories about Anavex Life Sciences (NASDAQ:AVXL) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Anavex Life Sciences earned a news impact score of 0.24 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.2347739387101 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Anavex Life Sciences (NASDAQ:AVXL) traded down $0.03 during midday trading on Friday, hitting $3.40. The company had a trading volume of 145,564 shares, compared to its average volume of 322,285. The stock has a market cap of $151.68, a PE ratio of -10.30 and a beta of 0.94. Anavex Life Sciences has a 52 week low of $3.01 and a 52 week high of $6.64.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Monday, December 11th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.02). equities analysts forecast that Anavex Life Sciences will post -0.44 EPS for the current year.

Several analysts have weighed in on the company. Noble Financial reaffirmed a “buy” rating on shares of Anavex Life Sciences in a report on Tuesday, December 12th. Maxim Group set a $14.00 price objective on Anavex Life Sciences and gave the company a “buy” rating in a report on Monday, December 11th. ValuEngine cut Anavex Life Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, November 21st. Finally, Zacks Investment Research raised Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Tuesday, September 26th.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Anavex Life Sciences (AVXL) Stock Price” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/01/13/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-anavex-life-sciences-avxl-stock-price.html.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Insider Buying and Selling by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.